eMethods

OUTCOMES AND ASSESSMENTS
The Epistaxis Severity Score (ESS) is derived from 6 questions about epistaxis frequency, epistaxis duration, epistaxis intensity, presence of anemia, need for blood transfusion, and need to seek medical care 1 . For this study the ESS at all time points was based on the patient's epistaxis during the prior 4 weeks. It has a range of 0-10 where 0-3.99 is mild, 4-6.99 is moderate, and 7-10 is severe. The minimal important difference (MID) has been determined to be 0.41 via the anchor-based approach and 1.01 via the distribution-based approach, giving a mean MID of 0.71 2 . The decision to have blood transfusion, visit the emergency room, or seek any other type of care was at the discretion of the patient and investigator. However, in practice HHT patients do not usually receive transfusion unless the hemoglobin drops below 7-8 gm/dl.
Baseline assessments included: a history and physical examination; patient estimate of the number of epistaxis episodes per week during the 4 weeks prior to baseline; ESS; and phlebotomy for hemoglobin and ferritin. Each patient was contacted by phone at 1, 2, 4, and 8 weeks to monitor for side effects and to encourage compliance with epistaxis diary completion and drug use. Adverse events were reported and any new symptoms not present at baseline or worsening from baseline were tracked. Patients returned at 12 weeks to repeat the baseline assessments and return study drug. Patients were contacted by phone at 24 weeks to repeat the ESS and return the diary for weeks 13-24. [1] This is the form used to document and calculate the ESS. The bracketed numbers in blue after each response show how data were documented and analyzed for eTable 1 (these numbers were not present on the actual form that the patient would fill out). For example, most patients answered option 3, 4, or 5 for Question 1. As a result, the means for Question 1 averaged around 4. ) and can also be found online at: https://www2.drexelmed.edu/HHT-ESS/ eFigure. Descriptive profile of epistaxis frequency and duration over time (A) Epistaxis frequency reported as a weekly median value taken from the nosebleed diary. Active treatment was provided from baseline to week 12. The pre-specified analysis phase for the primary outcome is shaded in gray from week 5 to week 12. There was considerable variation in epistaxis frequency (data reported as median number of bleeds, IQR). No drug effects were seen. Between weeks 5 and 12 the following were observed: bevacizumab (7.0, 4.5-10.5), estriol (8.0, 4.0-12.0), tranexamic acid (7.5, 3.0-11.0), placebo (8.0, 3.0-14.0). An observation phase continued for weeks 13-24. The values for median (B) epistaxis duration per bleed were also derived from the nosebleed diary. The analysis phase for the secondary outcome is shaded in gray from week 5 to week 12. No drug effects were seen. Between weeks 5 and 12 the following were observed (median minutes of bleeding, IQR): bevacizumab (3.0, 1.6-5.5), estriol (4.0, 1.6-6.3), tranexamic acid (6.2, 3.0-9.4), placebo (5.0, 3.0-9.8). The complete list of adverse events reported by study participants, divided by organ system. The data reflect the number of patients experiencing an event, not the total number of events. § P < 0.05, Fisher's Exact Test. ¶ Tranexamic acid and placebo significantly greater than estriol after Bonferroni correction ‡ Tranexamic acid significantly greater than estriol and placebo after Bonferroni correction ∞ P < 0.01, Fisher's Exact Test. Tranexamic acid significantly greater than estriol and bevacizumab after Bonferroni correction * The percentages for these events were calculated for females only (N = bevacizumab 13, estriol 12, tranexamic acid 14, placebo 13).
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